← back to search

John M. Gansner

Alnylam Pharmaceuticals (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Kidney Stones and Urolithiasis Treatments, Biomedical Research and Pathophysiology, Porphyrin Metabolism and Disorders, and Chemotherapy-induced organ toxicity mitigation.
h-index
21
citations
2,171
works
70
NIH funding
primary concept
Primary hyperoxaluria
email

Recent publications

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Frontiers in Pediatrics 2024cited by 8position: middledoi
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases 2022cited by 81position: middledoi
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
Pediatric Nephrology 2022cited by 44position: middledoi
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine 2021cited by 492position: middledoi
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Nature Communications 2021cited by 172position: middledoi
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports 2021cited by 31position: middledoi
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Nephrology Dialysis Transplantation 2020cited by 21position: middledoi
Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche
Nature 2018cited by 89position: middledoi
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
The Lancet Haematology 2017cited by 519position: middledoi
Sorting zebrafish thrombocyte lineage cells with a Cd41 monoclonal antibody enriches hematopoietic stem cell activity
Blood 2017cited by 9position: firstdoi
Understanding the regulation of vertebrate hematopoiesis and blood disorders – big lessons from a small fish
FEBS Letters 2016cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yaacov Frishberg · University of Wisconsin–Madison6 papers (2020–2024)Daniella Magen · Technion – Israel Institute of Technology6 papers (2020–2024)Hadas Shasha‐Lavsky · Bar-Ilan University6 papers (2020–2024)Tracy L. McGregor · Vanderbilt University5 papers (2020–2022)David J. Sas · Mayo Clinic5 papers (2020–2024)John C. Lieske · Mayo Clinic4 papers (2020–2022)Anne‐Laure Sellier‐Leclerc · Inserm4 papers (2021–2024)Eva Šimková · Al Jalila Foundation4 papers (2020–2022)Jaap W. Groothoff · Amsterdam Neuroscience4 papers (2020–2022)Wesley Hayes · Hospital for Sick Children3 papers (2021–2024)Jeffrey M. Saland · Mount Sinai Hospital3 papers (2020–2021)Mini Michael · Texas Children's Hospital3 papers (2022–2024)Sander F. Garrelfs · Emma Kinderziekenhuis3 papers (2020–2021)Leonard I. Zon · Harvard University3 papers (2016–2018)Shabbir H. Moochhala · The Royal Free Hospital3 papers (2020–2021)Sally A. Hulton · Birmingham Women's Hospital3 papers (2020–2021)Marianne T. Sweetser · Alnylam Pharmaceuticals (United States)3 papers (2021–2022)Kristin Meliambro · Mount Sinai Health System3 papers (2020–2021)Michael J. Koren · National Health and Medical Research Council3 papers (2020–2021)Pierre Cochat · Institut des Maladies Génétiques Imagine2 papers (2020–2021)